Apyx Medical Corporation APYX
2.99 USD +0.40 (+15.44%)
Nov 5, 2026, 3:04 PM EST
2.58 Day range 3.11
2.25 52-week range 5.08
- YTD
- -14.57%
- 1 year
- -4.78%
News
seekingalpha.com Apyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript Apyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript
zacks.com Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates Apyx Medical (APYX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.05 per share a year ago.
benzinga.com Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.410M Est Apyx Medical (NASDAQ:APYX) affirms FY2026 sales outlook from $59.000 million-$60.000 million to $59.000 million-$60.000 million vs $59.410 million estimate.
benzinga.com Apyx Medical Q3 EPS $(0.04) Beats $(0.09) Estimate, Sales $14.030M Beat $13.290M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 20 percent increase over losses of $(0.05)…
globenewswire.com Apyx Medical Corporation Reports Third Quarter 2026 Financial Results Reported total revenue of $14.0 million in the third quarter of 2026 driven by 17% growth in the Surgical Aesthetics segment Initiated successful full commercial launch of the power liposuction…
prnewswire.com SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Apyx Medical Corporation (NASDAQ: APYX) NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) on behalf of the company's shareholders. The investigation…
globenewswire.com Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026 CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the…
globenewswire.com Apyx Medical Corporation to Participate in Upcoming Investor Conferences CLEARWATER, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the…
globenewswire.com Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics
marketbeat.com Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie…
defenseworld.net Apyx Medical Corporation (NASDAQ:APYX) Receives $6.60 Consensus Target Price from Brokerages Apyx Medical Corporation (NASDAQ: APYX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the stock, Marketbeat.com reports.…
seekingalpha.com Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript
marketbeat.com Apyx Medical Q2 Earnings Call Highlights Apyx Medical NASDAQ: APYX reported second-quarter revenue growth of 22% as sales in its surgical aesthetics business increased, led by adoption of its AYON Body Contouring System, international…
benzinga.com Apyx Medical Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $13.884M Beat $13.175M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 22.22 percent increase over losses of $(0.09)…- benzinga.com Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.554M Est Apyx Medical (NASDAQ:APYX) affirms FY2026 sales outlook from $59.000 million-$60.000 million to $59.000 million-$60.000 million vs $59.554 million estimate.
globenewswire.com Apyx Medical Corporation Reports Second Quarter 2026 Financial Results CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the…
globenewswire.com Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and…
globenewswire.com Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the…
benzinga.com This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Wall Street analysts changed outlook on top stocks. To see all changes, visit the analyst ratings page. FAST stock has a Buy rating with $55 PT.- benzinga.com HC Wainwright & Co. Initiates Coverage On Apyx Medical with Buy Rating, Announces Price Target of $7 HC Wainwright & Co. analyst Yi Chen initiates coverage on Apyx Medical (NASDAQ:APYX) with a Buy rating and announces Price Target of $7.
benzinga.com Apyx Medical Appoints Stavros Vizirgianakis Executive Chairman, Effective June 11 https://www.sec.gov/ix?doc=/Archives/edgar/data/719135/000149315226029081/form8-k.htm
prnewswire.com Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway CLEARWATER, Fla., May 27, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON…
benzinga.com Apyx Medical Publishes New Clinical Data In Aesthetic Surgery Journal Open Forum Highlighting Approach To Improving Cellulite And Skin Laxity In this study, 22 patients received a single treatment session combining these modalities to address both the structural and surface level causes of cellulite and skin laxity. Results showed…
globenewswire.com New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion® Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach Published data demonstrates visible reduction in dimpling and progressive…- benzinga.com Apyx Medical Announces Publication Of A New Retrospective Investigator-Initiated Study In Plastic And Reconstructive Surgery - Global Open The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion).The results demonstrate that adding Renuvion to liposuction resulted in…
globenewswire.com Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the…
globenewswire.com Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™ Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON Addition of the power liposuction capability as a…
seekingalpha.com Apyx Medical Corporation (APYX) Q1 2026 Earnings Call Transcript Apyx Medical Corporation (APYX) Q1 2026 Earnings Call Transcript
zacks.com Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates Apyx Medical (APYX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.1 per share a year ago.- benzinga.com Apyx Medical Raises FY2026 Sales Guidance from $57.500M-$58.500M to $59.000M-$60.000M vs $57.988M Est Apyx Medical (NASDAQ:APYX) raises FY2026 sales outlook from $57.500 million-$58.500 million to $59.000 million-$60.000 million vs $57.988 million estimate.
benzinga.com Apyx Medical Q1 EPS $(0.05) Beats $(0.10) Estimate, Sales $12.490M Beat $10.868M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50 percent. This is a 50 percent increase over losses of $(0.10) per…
globenewswire.com Apyx Medical Corporation Reports First Quarter 2026 Financial Results CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the…
globenewswire.com Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026 CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the…- benzinga.com Craig-Hallum Maintains Buy on Apyx Medical, Raises Price Target to $6 Craig-Hallum analyst Matthew Hewitt maintains Apyx Medical (NASDAQ:APYX) with a Buy and raises the price target from $5 to $6.
benzinga.com This JM Smucker Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Wall Street analysts upgraded Uniqure NV, Apyx Medical Inc, J M Smucker Co, and VTEX with raised price targets. See analyst ratings page.
benzinga.com Earnings Scheduled For March 10, 2026 
benzinga.com Earnings Breakdown: Apyx Medical Q4 - benzinga.com Apyx Medical Sees FY2026 Sales $57.500M-$58.500M vs $55.480M Est Apyx Medical (NASDAQ:APYX) sees FY2026 sales of $57.500 million-$58.500 million vs $55.480 million analyst estimate.
- benzinga.com Apyx Medical Q4 EPS $(0.03) Beats $(0.06) Estimate, Sales $19.164M Beat $18.160M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 46.43 percent. This is a 75 percent increase over losses of $(0.12)…
benzinga.com A Preview Of Apyx Medical's Earnings 
benzinga.com Roth Capital Initiates Coverage On Apyx Medical with Buy Rating, Announces Price Target of $6 Roth Capital analyst Kyle Bauser initiates coverage on Apyx Medical (NASDAQ:APYX) with a Buy rating and announces Price Target of $6.- benzinga.com Apyx Medical Announces Approval, Commercial Roll Out Of Apyx One Console, Single-Use Handpieces In South Korea Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced…
benzinga.com Apyx Medical Reveals Proposed Public Offering of Common Stock; No Size Disclosed Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced…- benzinga.com Citizens Upgrades Apyx Medical to Market Outperform, Announces $8 Price Target Citizens analyst David Turkaly upgrades Apyx Medical (NASDAQ:APYX) from Market Perform to Market Outperform and announces $8 price target.
- benzinga.com Apyx Medical Raises FY2025 Sales Guidance from $50.000M-$52.000M to $50.500M-$52.500M vs $50.001M Est Apyx Medical (NASDAQ:APYX) raises FY2025 sales outlook from $50.000 million-$52.000 million to $50.500 million-$52.500 million vs $50.001 million estimate.
- benzinga.com Apyx Medical Q3 EPS $(0.05) Beats $(0.10) Estimate, Sales $12.877M Beat $12.002M Estimate Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50.98 percent. This is a 64.29 percent increase over losses of…
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com Apyx Medical Submits FDA 510(k) For Device Label Expansion Of AYON Body Contouring System Initiated Nationwide Commercial Launch of AYON in SeptemberThe Company is Hosting a Virtual Key Opinion Leader Event to Discuss the Commercial Launch of AYON on October 14, 2
benzinga.com Earnings Scheduled For August 7, 2025